This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Advances in the Multidisciplinary Management of Hepatocellular Carcinoma (HCC): Strategies for Incorporating Emerging Immunotherapy Treatment Options

Advances in the Multidisciplinary Management of Hepatocellular Carcinoma (HCC): Strategies for Incorporating Emerging Immunotherapy Treatment Options



Time to Complete

30 minutes


March 30, 2018


March 30, 2019
Add to Queue

Maximum Credits

0.50 / AMA PRA Category 1 CreditTM

Accredited Provider

Sponsored by the Academy for Continued Healthcare Learning.

Commercial Supporter

This activity is supported by an educational grant from Merck & Co., Inc.

Program Description

Expert faculty Richard Finn, MD, discusses treatment options and strategies in a case-based approach for two patients who have failed conventional therapies and may be candidates for immunotherapy. The activity features an online virtual patient platform that affords clinicians an opportunity to absorb relevant clinical and evidence-based information.

Intended Audience

This activity is intended for physicians (oncologists, interventional radiologists, hepatologists) and other clinicians who care for patients with hepatocellular carcinoma (HCC).

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Differentiate the mechanisms of action and scientific rationale of currently available systemic therapies with the use of immunotherapy approaches in advanced HCC
  • Discuss the role of new and emerging immunotherapies in current treatment paradigms for advanced HCC
  • Review the efficacy, safety and tolerability of emerging agents for advanced HCC and the management of immune-related adverse events
  • Evaluate the evolving immunotherapeutic research landscape, including ongoing studies in earlier stages of disease as well as personalized and locoregional therapies

Conflict Of Interest Disclosure Policy

Guidelines require that participants in CME/CE activities be made aware of all financial relationships that may be perceived as affecting the presentation of the faculty member. ACHL ensures that all faculty and staff involved in the planning, development, and implementation of ACHL activities disclose relevant financial relationships and that conflicts of interest are resolved before the CME/CE activity occurs. Complete information will be provided to participants prior to the start of the educational activity.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.


Richard S. Finn, MD
Associate Professor of Medicine
Medicine, Division of Hematology/Oncology
Geffen School of Medicine at UCLA
Los Angeles, CA

Dr. Finn discloses the following:
Consulting Agreements: Bayer, Bristol-Myers Squibb, Eisai, Merck & Co., Pfizer, Eli Lilly
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Lenvatinib, Pembrolizimab

Staff Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM .   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion


The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.


To obtain credit, a score of 100% on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact:
Laurie Novoryta


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue